SAN DIEGO–(BUSINESS WIRE)–Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today announced that company leadership will participate virtually in the UBS Biotechnology Private Company Symposium, to be held September 21-22, 2022. Pipeline will provide a company overview and lead one-on-one virtual meetings with investors during the conference.
About Pipeline Therapeutics
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of cutting-edge therapies for precision neuroregeneration, including myelin restoration, synaptogenesis and axonal repair. The Society has a wide range of programs to treat multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials – an SAD/MAD study and a PET study – in healthy volunteers, and received Investigational New Drug Clearance from the Food and Drug Administration. to initiate clinical development in relapses. MS patients in remission.
For more information, visit www.pipelinetherapeutics.com and connect with us on LinkedIn.